A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

STUDY OVERVIEW

This observational study is sponsored by Bayer and will collect real-world data on finerenone use in people with chronic kidney disease (CKD) and type 2 diabetes (T2D). CKD, worsened by high blood sugar in T2D, reduces the kidneys' filtering ability. Finerenone, which blocks damaging proteins, is approved for these conditions. Researchers will gather information on treatment patterns, reasons for starting or stopping finerenone, dosing, concurrent medications, and adverse events, especially hyperkalemia. U.S. participants may provide blood and urine samples for further analysis. Each participant will be followed for 12 months, or until early discontinuation or the study's planned end in September 2027.

STUDY GOALS

The goal of this study is to gather real-world data on the treatment patterns, efficacy, and safety of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).

LOCATION

El Paso, Texas: Academy of Diabetes, Thyroid and Endocrine

INCLUSION CRITERIA

  • Adults (≥18 years old)

  • Diagnosed with CKD associated with T2D

  • Receiving finerenone (10 or 20 mg) within 8 weeks before or after signing informed consent

  • Decision to start finerenone made before signing informed consent

  • Signed informed consent

exclusion criteria

  • Participation in any investigational trial during the study

  • Contraindications as per local label

For more information, visit ClinicalTrials.gov.